Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 5, 2017, Pages 751-759

  Petrykiv, Sergei ^a   David Sjostrom C ^b   Greasley, Peter J ^b   Xu, John ^c   Persson, Frederik ^d   Heerspink, Hiddo J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d STENO DIABETES CENTER   (Denmark)

Author keywords

Albuminuria; Benzhydryl Compounds; Blood pressure; Body Weight; Cardiovascular; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic nephropathy; Glomerular filtration rate; Glucosides; Hematocrit; Humans; Hypoglycemic Agents; Natriuresis; Risk factors

Indexed keywords

ALBUMIN; BICARBONATE; CREATININE; DAPAGLIFLOZIN; HEMOGLOBIN A1C; PLACEBO; URIC ACID; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; ALBUMIN TO CREATININE RATIO; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR RISK; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENITAL TRACT INFECTION; HEMATOCRIT; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; UROGENITAL SYSTEM PARAMETERS; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASE; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; KIDNEY PROXIMAL TUBULE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROTECTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; URINE;

AGED; ALBUMINURIA; BENZHYDRYL COMPOUNDS; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HEMOGLOBINS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MALE; MIDDLE AGED; PROTECTIVE FACTORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 85021694438     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.10180916     Document Type: Article

References (36)

1. List JF, Woo V, Morales E, Tang W, Fiedorek FT: Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32: 650-657, 2009
2. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF: Effect ofdapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebocontrolled trial. Lancet 375: 2223-2233, 2010
3. Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI: Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134: 752-772, 2016
4. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjöström CD: Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 18: 590-597, 2016
5. Fioretto P, Stefansson BV, Johnsson E, Cain VA, Sjöström CD: Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia 59: 2036-2039, 2016
6. Sjöström CD, Johansson P, Ptaszynska A, List J, Johnsson E: Dapagliflozin lowers blood pressure in hypertensive and nonhypertensive patients with type 2 diabetes. Diab Vasc Dis Res 12: 352-358, 2015
7. Kohan DE, Fioretto P, Tang W, List JF: Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85: 962-971, 2014
8. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators: Efficacy and safetyof empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2: 369-384, 2014
9. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF: Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic controlby diet and exercise:Arandomized, double-blind, placebocontrolled, phase 3 trial. Diabetes Care 33: 2217-2224, 2010
10. Bolinder J, Ljunggren O¨, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S: Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97: 1020-1031, 2012
11. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group: Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med 156: 405-415, 2012
12. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: A randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13: 928-938, 2011
13. Rosenstock J, Vico M, Wei L, Salsali A, List JF: Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35: 1473-1478, 2012
14. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF: Dapagliflozin, metformin XR, or both: Initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 66: 446-456, 2012
15. Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ: Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: A 24-week, multicenter, randomized, double-blind, placebocontrolled study with a 28-week extension. J Am Geriatr Soc 62: 1252-1262, 2014
16. Jabbour SA, Hardy E, Sugg J, Parikh S; Study 10 Group: Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 37: 740-750, 2014
17. Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ: Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 38: 1218-1227, 2015
18. Heerspink HJ, Grobbee DE, de Zeeuw D: A novel approach for establishing cardiovascular drug efficacy. Nat Rev Drug Discov 13: 942, 2014
19. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117-2128, 2015
20. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323-334, 2016
21. Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I: Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: A meta-analysis. Cardiovasc Diabetol 15: 37, 2016
22. Rajasekeran H, Lytvyn Y, Cherney DZ: Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: The emerging role of natriuresis. Kidney Int 89: 524-526, 2016
23. Krikken JA, Laverman GD, Navis G: Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr Opin Nephrol Hypertens 18: 531-538, 2009
24. Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, Groen H, Laverman GD, Navis G; Holland Nephrology Study (HONEST) Group: Effects of sodium restrictionandhydrochlorothiazide onRAAS blockade efficacy in diabetic nephropathy: A randomised clinical trial. Lancet Diabetes Endocrinol 2: 385-395, 2014
25. Novikov A, Vallon V: Sodium glucose cotransporter2inhibition in the diabetic kidney: An update. CurrOpin Nephrol Hypertens 25: 50-58, 2016
26. Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G: Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25: 2028-2039, 2014
27. + exchanger NHE3: Effects on bicarbonate absorption and ammonium excretion. J Mol Med (Berl) 91: 951-963, 2013
28. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J: Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15: 853-862, 2013
29. Bolinder J, Ljunggren ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S: Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetesmellitus inadequately controlled on metformin. Diabetes Obes Metab 16: 159-169, 2014
30. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: A randomized, doubleblind, placebo-controlled 102-week trial. BMCMed 11: 43, 2013
31. Bailey CJ, Morales Villegas EC, Woo V, Tang W, Ptaszynska A, List JF: Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: A randomized double-blind placebocontrolled 102-week trial. Diabet Med 32: 531-541, 2015
32. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter type 2. Clin Pharmacokinet 53: 17-27, 2014
33. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy:Post hoc analysis fromtheReductionof Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18: 1540-1546, 2007
34. Schievink B, de Zeeuw D, Parving HH, Rossing P, Lambers Heerspink HJ: The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. Br J Clin Pharmacol 80: 678-686, 2015
35. Heerspink HJ, Ninomiya T, Persson F, Brenner BM, Brunel P, Chaturvedi N, Desai AS, Haffner SM, Mcmurray JJ, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D: Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of theALTITUDE trial. DiabetesObesMetab 18: 169-177, 2016
36. Cherney D, Lund SS, Perkins BA, Groop PH, Cooper ME, Kaspers S, Pfarr E, Woerle HJ, von Eynatten M: The effect of sodiumglucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59: 1860-1870, 2016